J L Masferrer

Summary

Affiliation: Monsanto Company
Country: USA

Publications

  1. ncbi request reprint Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
    J L Masferrer
    GD Searle Monsanto Company, St Louis, Missouri 63167, USA
    Cancer Res 60:1306-11. 2000
  2. ncbi request reprint COX-2 inhibitors. A new class of antiangiogenic agents
    J L Masferrer
    Discovery Pharmacology and Analytical Sciences Center, G D Searle Monsanto Company, St Louis, Missouri 63167, USA
    Ann N Y Acad Sci 889:84-6. 1999
  3. pmc Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors
    D Salvemini
    G D Searle Co, St Louis, Missouri 63167, USA
    J Clin Invest 96:301-8. 1995
  4. ncbi request reprint Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers
    A T Koki
    Pharmacia Corporation, 700 Chesterfield Pkway N, BB3K, St Louis, MO 63198, USA
    Prostaglandins Leukot Essent Fatty Acids 66:13-8. 2002
  5. pmc Regulation of prostaglandin production by nitric oxide; an in vivo analysis
    D Salvemini
    G D Searle, Department of Molecular Pharmacology, St Louis, MO 63167, USA
    Br J Pharmacol 114:1171-8. 1995
  6. pmc Pharmacological analysis of cyclooxygenase-1 in inflammation
    C J Smith
    Searle Research and Development, 700 Chesterfield Parkway North, St Louis, MO 63198, USA
    Proc Natl Acad Sci U S A 95:13313-8. 1998

Detail Information

Publications6

  1. ncbi request reprint Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors
    J L Masferrer
    GD Searle Monsanto Company, St Louis, Missouri 63167, USA
    Cancer Res 60:1306-11. 2000
    ..The ability of celecoxib to block angiogenesis and suppress tumor growth suggests a novel application of this anti-inflammatory drug in the treatment of human cancer...
  2. ncbi request reprint COX-2 inhibitors. A new class of antiangiogenic agents
    J L Masferrer
    Discovery Pharmacology and Analytical Sciences Center, G D Searle Monsanto Company, St Louis, Missouri 63167, USA
    Ann N Y Acad Sci 889:84-6. 1999
    ..This novel antiangiogenic activity of COX-2 inhibitors indicates their potential therapeutic utility in several types of cancer...
  3. pmc Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors
    D Salvemini
    G D Searle Co, St Louis, Missouri 63167, USA
    J Clin Invest 96:301-8. 1995
    ....
  4. ncbi request reprint Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers
    A T Koki
    Pharmacia Corporation, 700 Chesterfield Pkway N, BB3K, St Louis, MO 63198, USA
    Prostaglandins Leukot Essent Fatty Acids 66:13-8. 2002
    ..These data collectively imply COX-2 may play an important role during premalignant hyperproliferation, as well as the later stages of invasive carcinoma and metastasis in various human epithelial cancers...
  5. pmc Regulation of prostaglandin production by nitric oxide; an in vivo analysis
    D Salvemini
    G D Searle, Department of Molecular Pharmacology, St Louis, MO 63167, USA
    Br J Pharmacol 114:1171-8. 1995
    ....
  6. pmc Pharmacological analysis of cyclooxygenase-1 in inflammation
    C J Smith
    Searle Research and Development, 700 Chesterfield Parkway North, St Louis, MO 63198, USA
    Proc Natl Acad Sci U S A 95:13313-8. 1998
    ..These results suggest that, in addition to the role of peripherally produced PGs, there is a critical, centrally mediated neurological component to inflammatory pain that is mediated at least in part by COX-2...